半乳糖凝集素-1在免疫中的利弊:它在免疫细胞功能、细胞凋亡和癌症免疫治疗中的作用,重点是T细胞。

IF 7.9 2区 医学 Q1 IMMUNOLOGY
Julianna Novák, Tamás Takács, Álmos Tilajka, Loretta László, Orsolya Oravecz, Emese Farkas, Nándor Gábor Than, László Buday, Andrea Balogh, Virág Vas
{"title":"半乳糖凝集素-1在免疫中的利弊:它在免疫细胞功能、细胞凋亡和癌症免疫治疗中的作用,重点是T细胞。","authors":"Julianna Novák, Tamás Takács, Álmos Tilajka, Loretta László, Orsolya Oravecz, Emese Farkas, Nándor Gábor Than, László Buday, Andrea Balogh, Virág Vas","doi":"10.1007/s00281-025-01047-8","DOIUrl":null,"url":null,"abstract":"<p><p>Galectin-1 (Gal-1), a member of the β-galactoside-binding soluble lectin family, is a double-edged sword in immunity. On one hand, it plays a crucial role in regulating diverse immune cell functions, including the apoptosis of activated T cells. These processes are key in resolving inflammation and preventing autoimmune diseases. On the other hand, Gal-1 has significant implications in cancer, where tumor cells and the tumor microenvironment (TME) (e.g., tumor-associated fibroblasts, myeloid-derived suppressor cells) secrete Gal-1 to evade immune surveillance and promote cancer cell growth. Within the TME, Gal-1 enhances the differentiation of tolerogenic dendritic cells, induces the apoptosis of effector T cells, and enhances the proliferation of regulatory T cells, collectively facilitating tumor immune escape. Therefore, targeting Gal-1 holds the potential to boost anti-tumor immunity and improve the efficacy of cancer immunotherapy. This review provides insights into the intricate role of Gal-1 in immune cell regulation, with an emphasis on T cells, and elucidates how tumors exploit Gal-1 for immune evasion and growth. Furthermore, we discuss the potential of Gal-1 as a therapeutic target to augment current immunotherapies across various cancer types.</p>","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"47 1","pages":"24"},"PeriodicalIF":7.9000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968517/pdf/","citationCount":"0","resultStr":"{\"title\":\"The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells.\",\"authors\":\"Julianna Novák, Tamás Takács, Álmos Tilajka, Loretta László, Orsolya Oravecz, Emese Farkas, Nándor Gábor Than, László Buday, Andrea Balogh, Virág Vas\",\"doi\":\"10.1007/s00281-025-01047-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Galectin-1 (Gal-1), a member of the β-galactoside-binding soluble lectin family, is a double-edged sword in immunity. On one hand, it plays a crucial role in regulating diverse immune cell functions, including the apoptosis of activated T cells. These processes are key in resolving inflammation and preventing autoimmune diseases. On the other hand, Gal-1 has significant implications in cancer, where tumor cells and the tumor microenvironment (TME) (e.g., tumor-associated fibroblasts, myeloid-derived suppressor cells) secrete Gal-1 to evade immune surveillance and promote cancer cell growth. Within the TME, Gal-1 enhances the differentiation of tolerogenic dendritic cells, induces the apoptosis of effector T cells, and enhances the proliferation of regulatory T cells, collectively facilitating tumor immune escape. Therefore, targeting Gal-1 holds the potential to boost anti-tumor immunity and improve the efficacy of cancer immunotherapy. This review provides insights into the intricate role of Gal-1 in immune cell regulation, with an emphasis on T cells, and elucidates how tumors exploit Gal-1 for immune evasion and growth. Furthermore, we discuss the potential of Gal-1 as a therapeutic target to augment current immunotherapies across various cancer types.</p>\",\"PeriodicalId\":21704,\"journal\":{\"name\":\"Seminars in Immunopathology\",\"volume\":\"47 1\",\"pages\":\"24\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2025-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968517/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in Immunopathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00281-025-01047-8\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Immunopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00281-025-01047-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

半乳糖凝集素-1 (Gal-1)是β-半乳糖苷结合可溶性凝集素家族的一员,在免疫中是一把双刃剑。一方面,它在调节多种免疫细胞功能,包括活化T细胞的凋亡中起着至关重要的作用。这些过程是解决炎症和预防自身免疫性疾病的关键。另一方面,Gal-1在癌症中具有重要意义,肿瘤细胞和肿瘤微环境(TME)(如肿瘤相关成纤维细胞、髓源性抑制细胞)分泌Gal-1以逃避免疫监视并促进癌细胞生长。在TME内,Gal-1增强耐受性树突状细胞的分化,诱导效应T细胞的凋亡,增强调节性T细胞的增殖,共同促进肿瘤免疫逃逸。因此,靶向Gal-1具有增强抗肿瘤免疫和提高肿瘤免疫治疗效果的潜力。这篇综述提供了Gal-1在免疫细胞调控中的复杂作用,重点是T细胞,并阐明了肿瘤如何利用Gal-1进行免疫逃避和生长。此外,我们还讨论了Gal-1作为治疗靶点的潜力,以增强当前针对各种癌症类型的免疫疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells.

Galectin-1 (Gal-1), a member of the β-galactoside-binding soluble lectin family, is a double-edged sword in immunity. On one hand, it plays a crucial role in regulating diverse immune cell functions, including the apoptosis of activated T cells. These processes are key in resolving inflammation and preventing autoimmune diseases. On the other hand, Gal-1 has significant implications in cancer, where tumor cells and the tumor microenvironment (TME) (e.g., tumor-associated fibroblasts, myeloid-derived suppressor cells) secrete Gal-1 to evade immune surveillance and promote cancer cell growth. Within the TME, Gal-1 enhances the differentiation of tolerogenic dendritic cells, induces the apoptosis of effector T cells, and enhances the proliferation of regulatory T cells, collectively facilitating tumor immune escape. Therefore, targeting Gal-1 holds the potential to boost anti-tumor immunity and improve the efficacy of cancer immunotherapy. This review provides insights into the intricate role of Gal-1 in immune cell regulation, with an emphasis on T cells, and elucidates how tumors exploit Gal-1 for immune evasion and growth. Furthermore, we discuss the potential of Gal-1 as a therapeutic target to augment current immunotherapies across various cancer types.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Seminars in Immunopathology
Seminars in Immunopathology 医学-病理学
CiteScore
19.80
自引率
2.20%
发文量
69
审稿时长
12 months
期刊介绍: The aim of Seminars in Immunopathology is to bring clinicians and pathologists up-to-date on developments in the field of immunopathology.For this purpose topical issues will be organized usually with the help of a guest editor.Recent developments are summarized in review articles by authors who have personally contributed to the specific topic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信